Medscape Medical News
3 COMMENT S - Feb 3, 2012 14:55 EST
Although there was an edge for warfarin for those treated for four or more years, there is "no compelling" reason to anticoagulate these patients, researchers say.

New Orleans, LA - Results of a large randomized comparison of aspirin vs warfarin in patients with heart failure and reduced ejection fraction show no overall difference in the combined primary outcome of death, ischemic stroke, or intracranial hemorrhage between treatment groups [1].

"In terms of clinical implications, given no overall benefit of warfarin and increased risk of bleeding, in spite of suggestive benefit at four years of treatment and beyond, there is no compelling evidence to use warfarin or aspirin for all patients," lead author Dr Shunichi Homma (Columbia University, New York) concluded.
Read full article »


Interventional/Surgery
Feb 3, 2012 09:30 EST

Heart failure and transplantation with Dr Ileana Piña
Editorial programs
Debate and dialogue between top cardiovascular specialists, produced by
theheart.org's editorial team
View all »